Though c-Fos immunohistochemistry may not fully capture the ensemble of D1-MSNs activated by levodopa, we did not see a change in the number of c-Fos-labeled D1-MSNs in dyskinesia over the course of treatment. This evidence concerns the gene FOS and Dyskinesia.